Cite
HARVARD Citation
Vlaar, A. et al. (2020). Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trial. Lancet. pp. e764-e773. [Online].